文献速递免疫规划

一项基于全国登记库的回顾性研究评估芬兰儿童首剂麻腮风疫苗的非特异性效应

A retrospective nationwide register-based study to evaluate the non-specific effects of first MMR vaccination among children in Finland.
PubMed 文献 · Vaccine · 2022-12-14

芬兰2011年将首剂麻腮风疫苗推荐接种月龄从18月改为12月,形成自然实验。该回顾性全国登记队列研究纳入2008至2012年出生儿童,比较11至12月龄与18至19月龄接种者的感染发病。早期接种组(N=79949)在主随访期感染少于晚期接种组(N=60965),IRR 0.84(95%CI 0.81-0.87),但对照随访期也见类似差异。结论认为无明确非特异性效应证据,尿路感染可能存在非特异性效应,需其他研究确认。

要点

  • 主随访期早期接种组感染少于晚期接种组,IRR 0.84(95%CI 0.81-0.87),但对照期也见类似差异。
  • 主随访期接种儿童尿路感染更少(IRR 0.73,95%CI 0.60-0.89),对照随访期未见。
  • 性别分层后,尿路感染差异见于女孩,男孩未见。

核心结论

  • 未发现麻腮风疫苗对感染性疾病发病有明确非特异性效应的证据。
  • 尿路感染可能存在非特异性效应。
  • 需要其他研究确认,尤其是来自高收入国家的研究。

研究设计与样本

  • 回顾性全国登记库队列研究,纳入2008至2012年出生的芬兰儿童。
  • 按麻腮风疫苗接种年龄分为早期接种组(11至12月龄)和晚期接种组(18至19月龄)。
  • 主随访期为13至17月龄,对照随访期为3至10月龄和20至35月龄。
  • 分析所有感染,并额外分析尿路感染和支气管炎,以损伤作为对照结局。

主要发现

  • 主随访期早期接种组(N=79949)感染少于晚期接种组(N=60965),IRR 0.84(95%CI 0.81-0.87)。
  • 对照随访期也观察到类似差异。
  • 主随访期接种儿童尿路感染更少(IRR 0.73,95%CI 0.60-0.89),对照随访期未见。
  • 性别分层后,尿路感染差异见于女孩,男孩未见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要其他研究确认,尤其是来自高收入国家的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: According to earlier studies, live vaccines like measles-mumps-rubella (MMR) vaccine could reduce also other infections than only the infections they are targeted against. This non-specific effect has been seen especially in studies in low-income countries and results from high-income countries have not been unambiguous. In 2011 Finland changed the recommended schedule for the first MMR vaccination from 18 months to 12 months of age. This change created a natural experiment for evaluating the potential non-specific effects. METHODS: This is a retrospective nationwide register-based cohort study of Finnish children born between 2008 and 2012. Children were divided into two cohorts by age at MMR vaccination: children administered early MMR vaccination (11 through 12 months of age) and late MMR vaccination (18 through 19 months of age). Morbidity was evaluated during the main follow-up period (from 13 to 17 months of age) and before any MMR vaccination (3 to 10 months) and after all were vaccinated with MMR (20 to 35 months) as control follow-up periods. We analyzed all infections and did additional analyzes for urinary tract infections (UTI) and bronchitis. Injuries were analyzed as a control outcome. RESULTS: Early MMR vaccinated children (N = 79949) had fewer infections compared to late MMR vaccinated (N = 60965) during the main follow-up period. The incidence rate ratio (IRR) was 0.84 (95 % confidence interval (95 % CI) 0.81-0.87). However, similar differences were also observed during the control follow-up periods. MMR vaccinated children had less UTI in the main follow-up period (IRR 0.73, 0.60-0.89) but not in the control follow-up periods. When stratified by sex, the difference was observed among girls but not in boys. CONCLUSION: No clear evidence was found for non-specific effects in infectious diseases morbidity. However, there could be a nonspecific effect on UTI. Confirmation is needed from other studies, especially from high-income countries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Palmu AAM, Nieminen H, Lahdenkari M, et al. A retrospective nationwide register-based study to evaluate the non-specific effects of first MMR vaccination among children in Finland. Vaccine. 2022. PMID: 36526506. doi:10.1016/j.vaccine.2022.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。